ASCO Meeting Abstracts -- Milowsky et al. 24 (18 Supplement): 4500 Table 1

Dose mg/m²	Schedule	$≥$ 50% PSA Decline	25–50% PSA Decline	Gr 2–3 Neuropathy	Gr 2–3 Nausea	Gr 2–3 Fatigue

120	q2wks	0/3	0/3	0/3	0/3	0/3
168	q2wks	1/3	0/3	0/3	0/3	0/3
236	q2wks	0/3	1/3	2/3	2/3	0/3
330	q2wks	2/6	2/6	4/6	2/6	2/6
330	q3wks	0/14	1/14	7/14	2/14	4/14
462	q3wks	0/4	1/4	1/4	1/4	0/4
330	d 1, 15q6wks	Ongoing